2[3]Aaron I.Diabetic neuropathy pathogenesis and therapy.The American Journal of Medicine, 1999,107(213): 17～26
3[4]Young MJ,Bennett JL, Liderty SA,et al. Rheological and microvascular parameters in diabetic peripheral neuropathy.ClinSci, 1996,90:185～ 187
4[6]徐叔云,卞如濂,陈修.药理实验方法学.北京:人民卫生出版社,1996.845～846
5[1]Wolz P, Krieglstein J: Neuroprotective activity of lipoic and dihydrolipoic acid. In: Fuchs J, Packer L, Zimmer G, eds.Lipoic Acid in Health and Disease. New York: Marcel Dekker1997:205 - 225.
6[2]Randie PJ: Regulatory interactions between lipids and carbohydrates:The glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998; 14:263 - 283.
7[3]Betteridge DJ: What is oxidative stress? Metabolism 2000;49:3 - 8.
8[4]Haffner SM: Clinical relevance of the oxidative stress concipt. Metabolism 2000; 49: 30 - 34.
9[5]Christen Y:Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S-629S.
10[6]Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D: Serum markers for oxidative stress and severity of diabetic retnopathy. Diabetes Care 2000; 23: 234 -240.
8Bragd J,Adamson U,B cklund L,et al.Can glycaemic variability,ascalculated from blood glucose self-monitoring,predict the develop-ment of complications in type 1 diabetes over a decade?[J].DiabetesMetab.,2008,34(6):612-616.
9Alrawahi AH,Rizvi SG,Al-Riyami D,et a1.Prevalence and riskfactors of diabetic nephropathy in omani type 2 diabetics in Al-dakhiliyah region[J].Oman Med J,2012,27(3):212-216.
10Salgado PP,Silva IN,Vieira EC,et a1.Risk factors for early onsetof diabetic nephropathy in pediatric type 1 diabetes[J].J PediatrEndocrinol Metab,2010,23(12):1311-1320.
